Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a critical regulator of inflammatory signalling through toll‐like receptors 4 and 7/8 in murine and human lungs
These data demonstrate a key role for IRAK4 signalling in lung inflammation and suggest that IRAK4 inhibition has potential utility to treat lung diseases characterized by inflammatory responses driven through TLR4 and TLR7/8.
Authors
- Dhruma Thakker
- Marc A. Grundl
- Charlotte K. Billington
- Stefan Kreideweiß
- Thierry Bouyssou
- Sebastian Kreuz (ORCID: https://orcid.org/0000-0001-5905-5434)
- Sven Thamm (ORCID: https://orcid.org/0000-0002-8799-1155)
- Ian P. Hall (ORCID: https://orcid.org/0000-0001-9933-3216)
- Ian Sayers (ORCID: https://orcid.org/0000-0001-5601-5410)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- University of Nottingham (GB)
- Nottingham Biomedical Research Centre (GB)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1111/bph.16509
- Citations
- 3
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Boehringer Ingelheim
- National Institute for Health and Care Research
- Medical Research Council
- NIHR Nottingham Biomedical Research Centre